Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $400.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 34.79% from the company's current price.
Other analysts have also issued research reports about the company. Citigroup upped their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Raymond James upped their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. Leerink Partners increased their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a "market perform" rating in a report on Tuesday, June 25th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $286.82.
View Our Latest Stock Analysis on ALNY
NASDAQ:ALNY opened at $296.75 on Friday. The stock's fifty day moving average is $271.29 and its two-hundred day moving average is $215.60. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market capitalization of $37.54 billion, a price-to-earnings ratio of -110.73 and a beta of 0.39.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter last year, the company earned ($2.21) earnings per share. The firm's revenue for the quarter was up 107.0% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current fiscal year.
In other news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the firm's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company's stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,398 shares of company stock worth $13,595,460. Company insiders own 1.50% of the company's stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Souders Financial Advisors lifted its position in Alnylam Pharmaceuticals by 1.0% in the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company's stock valued at $853,000 after purchasing an additional 36 shares during the period. V Square Quantitative Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 21.9% during the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company's stock valued at $81,000 after acquiring an additional 60 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 91 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1.1% during the 1st quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company's stock valued at $1,632,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.